Foghorn Therapeutics (FHTX) EBT (2020 - 2025)
Historic EBT for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' EBT rose 1387.41% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 1597.54%. This contributed to the annual value of -$86.6 million for FY2024, which is 804.67% up from last year.
- Latest data reveals that Foghorn Therapeutics reported EBT of -$16.5 million as of Q3 2025, which was up 1387.41% from -$18.8 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' EBT registered a high of -$13.6 million during Q3 2023, and its lowest value of -$29.9 million during Q1 2023.
- Over the past 5 years, Foghorn Therapeutics' median EBT value was -$23.8 million (recorded in 2021), while the average stood at -$23.6 million.
- In the last 5 years, Foghorn Therapeutics' EBT crashed by 6890.29% in 2021 and then skyrocketed by 4719.62% in 2023.
- Quarter analysis of 5 years shows Foghorn Therapeutics' EBT stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then grew by 23.42% to -$22.1 million in 2023, then grew by 11.83% to -$19.5 million in 2024, then increased by 15.56% to -$16.5 million in 2025.
- Its EBT stands at -$16.5 million for Q3 2025, versus -$18.8 million for Q2 2025 and -$20.2 million for Q1 2025.